Israel's Treasury-Proposed Health Deficit Plans Opposed

11 August 1996

Israeli Health Minister Zachy Hanegbi has stated that the Treasury-proposed rise in patient copayments for visits to physicians and specialist clinics (Marketletter July 22) represents the placing of responsibility for budgetary cuts onto patients by means of a regressive tax on those needing health care services. According to the Minister, the decision is not justified, and is irrational and of uncertain medical consequences.

At a meeting of the Knesset (parliament) Labor & Social Affairs Committee, Mr Hanegbi will propose alternatives to those suggested by the Treasury, otherwise he forecast a breakdown in the health care system, the cost of which would be awesome. Mr Hanegbi added that the basket of services require updating as a result of technological developments and the introduction of new treatments and drugs.

The former Health Minister, Ephraim Sneh, had proposed adding to the National Health Insurance Law an amendment which would allow for these factors (plus the aging population), but the Treasury strongly opposed this move. Mr Hanegbi has said he will be active in locating and bringing about reforms, the costs of which will be reasonable and which can improve the situation for citizens.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight